Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.18 USD | +2.19% | -11.82% | -51.76% |
05-10 | UBS Cuts Price Target on ACADIA Pharmaceuticals to $25 From $27, Keeps Buy Rating | MT |
05-10 | Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $17 From $19, Maintains Perform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.76% | 2.46B | |
+26.12% | 49.18B | |
+0.77% | 42.11B | |
+49.96% | 40.37B | |
-5.26% | 28.85B | |
+13.31% | 26.09B | |
-22.48% | 18.71B | |
+8.61% | 13.26B | |
+32.25% | 12.32B | |
+0.39% | 11.99B |
- Stock Market
- Equities
- ACAD Stock
- News ACADIA Pharmaceuticals Inc.
- Needham Upgrades ACADIA Pharmaceuticals to Buy From Hold, Price Target is $37